NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases

We're now on Instagram! Follow us @NIMHgov SCIENCE NEWS NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program, aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases. Read about this partnership

NIMH Science News Questions? Contact NIMH! Director's Messages SUBSCRIBER SERVICES: Manage Preferences  |  Unsubscribe  |  Help

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Mental Health · 6001 Executive Boulevard · Bethesda, MD 20892-9663 · 1-866-615-6464